Can a common diabetes drug help transplant patients?

NCT ID NCT00466518

Completed Disease control Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how sitagliptin (Januvia) affects levels of anti-rejection drugs and blood sugar in 16 people who had a kidney transplant and have type 2 diabetes. Participants took sitagliptin daily for 3 months. The goal was to see if it is safe and works well in this group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sitagliptin (Januvia)
What this could lead to: If successful, this could show that sitagliptin is a safe and effective option to help control blood sugar in kidney transplant patients with type 2 diabetes.
What could go wrong: This is a very small, early-phase study with only 16 participants, so results may not apply to everyone. The main goal was to check drug interactions, not to prove long-term benefits or safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT TYPE 2 DIABETES

Contacts and locations

Locations

University of Nebraska Medical Center

Omaha, Nebraska, 68198-1230, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.